Skip to content
Winnowleaf home

Condition

Cushing's Disease

Cushing's disease is a hormone condition in which a small pituitary tumor makes too much ACTH, driving the adrenal glands to overproduce cortisol. In a phase III trial of pasireotide, a medicine with strong evidence, 25% reached normal urinary cortisol by six months and 76% saw levels fall. Cortisol dropped within two months and stayed lower for up to 24 months, but roughly three in four people still did not reach normal levels.

Sources: PMID 25537481

Supplements studied
0
Medicines and peptides
1
Graded outcomes
3
No supplement studies yetWe haven’t found supplement studies for Cushing's Disease. The medicines and peptides studied for it are listed below.

Prescription medicines and peptides studied, for context

These are not supplements. Most need a prescription, and some are research compounds with no approved use.

1 medicine or peptide

Pasireotide (Signifor)

Pasireotide (Signifor): outcomes studied for Cushing's Disease
GradeOutcomeEffectSizeStudiesPeopleStudies list
Cushing's Disease Symptoms

Improvements in clinical signs including weight, blood pressure, and metabolic parameters maintained over 24 months of treatment.

Improves (the measure goes down)Moderate effect19 studies

Studies that measured cushing's disease symptoms

and 16 more on the Pasireotide (Signifor) page

ACTH Secretion

Direct inhibition of ACTH release from corticotroph adenomas. Phase II showed decreased ACTH in majority of patients within 15 days.

Improves (the measure goes down)Large effect18 studies

Studies that measured acth secretion

and 15 more on the Pasireotide (Signifor) page

Urinary Free Cortisol Normalization

Phase III: 25% achieved UFC normalization at 6 months. 76% showed UFC decrease. Rapid reduction within 1-2 months, sustained up to 24 months.

Improves (the measure goes down)Large effect17 studies

Studies that measured urinary free cortisol normalization

and 14 more on the Pasireotide (Signifor) page

Key findings

  • Cushing's Disease SymptomsPasireotide (Signifor)Improves (the measure goes down)
  • ACTH SecretionPasireotide (Signifor)Improves (the measure goes down)
  • Urinary Free Cortisol NormalizationPasireotide (Signifor)Improves (the measure goes down)

Studies cited

20 studies from PubMed

  1. Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis.Frontiers in endocrinology, 2022 · PMID 35846311
  2. Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.Frontiers in endocrinology, 2022 · PMID 35518928
  3. Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis.Frontiers in endocrinology, 2021 · PMID 34603209
  4. Meta-Analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.The American surgeon, 2020 · PMID 32870029
  5. Meta-analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.The American surgeon, 2020 · PMID 32684027
  6. Efficacy of Pasireotide for Prevention of Postoperative Pancreatic Fistula in Pancreatic Surgery: a Systematic Review and Meta-analysis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2020 · PMID 32207077
  7. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.Pituitary, 2019 · PMID 30483918
  8. Pasireotide - Mechanism of Action and Clinical ApplicationsFront Endocrinol (Lausanne), 2017 · PMID 29595102
  9. Medical Therapy with Pasireotide in Recurrent Cushing's Disease: Experience of Patients Treated for At Least 1 Year at a Single CenterPituitary, 2017 · PMID 28289402
  10. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trialPituitary, 2017 · PMID 25537481
  11. Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II studyPituitary, 2015 · PMID 23943009
  12. Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2014 · PMID 25003365
  13. Pasireotide: a review of its use in Cushing's diseaseDrugs, 2013 · PMID 23605695
  14. A 12-month phase 3 study of pasireotide in Cushing's diseaseN Engl J Med, 2012 · PMID 22397653
  15. Pasireotide for the treatment of Cushing's diseaseExpert Opin Investig Drugs, 2010 · PMID 20533892
  16. Medical treatment of Cushing's disease: somatostatin analogues and pasireotideNeuroendocrinology, 2010 · PMID 20829632
  17. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trialJ Clin Endocrinol Metab, 2009 · PMID 18957506
  18. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's diseaseIDrugs, 2007 · PMID 18041687
  19. Spirulina platensis Provides a Small Advantage in Vertical Jump and Sprint Performance But Does Not Improve Elite Rugby Players' Body CompositionJ Diet Suppl · PMID 33118429
  20. Skill execution and sleep deprivation: effects of acute caffeine or creatine supplementation - a randomized placebo-controlled trialJ Int Soc Sports Nutr · PMID 21324203